Comparison

CagriSema vs. Liraglutide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

CagriSema

CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.

Liraglutide

Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	CagriSema	Liraglutide
Germany	Unapproved	Prescription
United States	Unapproved	Prescription

Full entries

Frequently asked questions

What is the difference between CagriSema and Liraglutide?: CagriSema is classified as "Metabolic", while Liraglutide is classified as "Metabolic". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, CagriSema or Liraglutide?: The highest available evidence level is "Human RCT" for CagriSema and "Human RCT" for Liraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of CagriSema and Liraglutide in Germany and the United States?: Germany: CagriSema — Unapproved, Liraglutide — Prescription. United States: CagriSema — Unapproved, Liraglutide — Prescription. These are factual summaries with source and review date on the individual pages.

Country

CagriSema

Liraglutide

Germany

Unapproved

Prescription

United States

Unapproved

Prescription

Frequently asked questions

What is the difference between CagriSema and Liraglutide?

CagriSema is classified as "Metabolic", while Liraglutide is classified as "Metabolic". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, CagriSema or Liraglutide?

The highest available evidence level is "Human RCT" for CagriSema and "Human RCT" for Liraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of CagriSema and Liraglutide in Germany and the United States?

Germany: CagriSema — Unapproved, Liraglutide — Prescription. United States: CagriSema — Unapproved, Liraglutide — Prescription. These are factual summaries with source and review date on the individual pages.